TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

• Published in: Frontiers in immunology Vol. 8; p. 1203
• Main Authors: Kaufmann, Stefan H E, Dockrell, Hazel M, Drager, Nick, Ho, Mei Mei, McShane, Helen, Neyrolles, Olivier, Ottenhoff, Tom H M, Patel, Brij, Roordink, Danielle, Spertini, François, Stenger, Steffen, Thole, Jelle, Verreck, Frank A W, Williams, Ann
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers 04.10.2017; Frontiers Media S.A
• Subjects: bacille Calmette–Guérin; Bacteriology; biomarker; Cell Behavior; Cellular Biology; clinical trial; Genetics; Human genetics; Human health and pathology; Immunology; Infectious diseases; Life Sciences; Microbiology and Parasitology; portfolio management; Pulmonology and respiratory tract; tuberculosis; vaccination; clinical trial; discovery; tuberculosis; portfolio management; bacille Calmette–Guérin; biomarker; vaccination; bacille Calmette-Guérin
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2017.01203

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.